S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Sucampo Announces Publication of NICE Recommendation for AMITIZA(R) (Lubiprostone)|
|Sucampo Pharmaceuticals, Inc. Announces Second Quarter 2014 Financial Results and Corporate Update Teleconference and Webcast on August 5|
|Takeda and Sucampo Enter Into Global Licensing Agreement for AMITIZA(R) (lubiprostone)|
|Swissmedic Approves AMITIZA(R) (Lubiprostone) for the Treatment of Opioid-Induced Constipation|
|Sucampo Reports Second Quarter 2014 Financial Results and Corporate Update|
|Sucampo Announces New Exclusive Global Manufacturing and Supply Agreement for Lubiprostone|
|Sucampo and Takeda Launch Direct-to-Consumer Advertising Campaign for AMITIZA(R) (lubiprostone) for Chronic Idiopathic Constipation|
|Sucampo Announces Settlement Agreement That Resolves Patent Litigation in U.S. Related to AMITIZA|
|Sucampo Announces Departure of Chief Financial Officer|
|Clinical Data for AMITIZA(R) Lubiprostone to be Presented at the American College of Gastroenterology 2014 Annual Scientific Meeting|
Click above to view more mutual fund data and stats for scmp - Sucampo Pharmaceuticals Inc Class A.